Management of Recurrent and De Novo NAFLD/NASH after Liver Transplantation

Nonalcoholic steatohepatitis (NASH) is a growing indication for liver transplant whether the primary or secondary cause of liver disease, and it is expected to be the leading indication in the years to come. NASH recurs after transplant but the impact of the recurrence on allograft and patient outcomes is unclear. A group of multidisciplinary transplant practice providers convened at the International Liver Transplant Society NASH consensus conference with the purpose of determining the current knowledge and future directions for understanding the recurrence rates, risk and management of NASH in the transplant allograft. Specific questions relating to post transplant NASH were proposed and reviewed in detail with recommendations on future actions to fill the knowledge gaps. Corresponding Author: Kymberly D Watt, MD, Division of Gastroenterology and Hepatology, William J vonLeibig Transplant Center, 200 First St SW, Rochester MN 55905 USA, Phone: 507-266-1586, Email: Watt.Kymberly@mayo.edu Acknowledgement for Consensus collaboration with Dr Chiara Becchetti, Dr Sherrie Bhoori, Dr Adele D'Antoni, Dr Eleonora De Martin, Dr Annalisa Dolcet, Dr Christophe Duvoux, Dr Jimin Liu No Conflict of Interest for the authors. Contributions: all authors contributed to the writing of the manuscript. GG and KDW lead the consensus group and organized the consensus review meeting and writing of the manuscript. Additional members of the consensus meeting are acknowledged. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2yKo8hp